The recent JCO Precision Oncology study could bolster the research use case for Veracyte's Decipher GRID database in better defining prostate cancer subgroups.
Culmination Bio's 4.5 million biospecimens and longitudinal omics and clinical data may help Cofactor rapidly advance the OncoPrism assay into multiple cancer types.
The availability of multi-gene tests was most inconsistent across 53 European countries, and reimbursement was seen as the greatest barrier.
In new guidelines, an expert panel recommended IHC and PCR for certain cancer types and pointed out knowledge gaps supporting NGS in other settings.
The firm envisions marketing the 53-gene signature with its existing MammaPrint and BluePrint tests as a comprehensive platform for breast cancer treatment selection.
The test is first available to employees over age 50 covered under Intermountain's SelectHealth, but the health system has a bigger five-year plan.